Innovative Synthetic Molecule Reduces Visceral Fat and Boosts Sleep Quality

Recent research from the Pennington Biomedical Research Center in the United States, Proteimax Biotechnology in Israel, and the University of São Paulo's Biomedical Sciences Institute in Brazil has unveiled promising findings regarding a synthetic peptide known as Pep19. This molecule has demonstrated potential in decreasing visceral fat and enhancing sleep quality among obese adults. Pep19 is a lab-created version of a naturally occurring peptide found within human cells, and prior animal studies suggested its efficacy in combating obesity-related factors, such as blood sugar levels, cholesterol, and blood pressure.

Published in the journal Diabetes Metabolism Research and Reviews, the study highlights how Pep19 influences the endocannabinoid system—an essential regulator of metabolic processes, appetite, fat breakdown, and energy release. Unlike many obesity medications that target the central nervous system and often cause adverse side effects, Pep19 appears to act without significant risks. Animal tests confirmed its effectiveness and safety, setting the stage for human trials.

The clinical trial involved 24 volunteers aged 46 to 59, with body weights between 91 and 106 kg and BMI ranging from 30 to 35 kg/m². Over 60 days, participants were divided into three groups, receiving either a placebo, 2 mg, or 5 mg of Pep19 orally before bedtime in a triple-blind setup. The results revealed a notable 17% reduction in visceral fat among those who took 5 mg of Pep19, which is significant since visceral fat is strongly linked to cardiovascular disease and type 2 diabetes. Importantly, there was no reduction in lean body mass.

In addition to fat reduction, all participants receiving Pep19 reported improved sleep quality, an essential factor since poor sleep can exacerbate obesity and its related health issues. Remarkably, no side effects were observed during the study. Researchers also observed that Pep19 may promote the transformation of white fat—an energy reserve—into brown fat, which burns calories to produce heat and energy, similar to the body's response to cold temperatures. This conversion could be a key mechanism behind its fat-reducing effects.

Although these initial findings are promising, researchers emphasize the need for larger, longer-term clinical studies to confirm Pep19's efficacy and safety. The potential of this molecule as a practical and effective treatment option offers hope amid the ongoing search for safe anti-obesity therapies. According to team members, if further research validates these results, Pep19 could represent a breakthrough in metabolic health management and improve the quality of life for millions affected by obesity.

source: https://medicalxpress.com/news/2025-08-synthetic-molecule-visceral-fat.html